Therapeutic combinations for the treatment or prevention of psychotic disorders
First Claim
Patent Images
1. A composition comprising:
- (a) either a typical or atypical anti-psychotic drug;
(b) a compound of formula I;
or a pharmaceutically acceptable salt thereof, wherein;
designates a single or double bond;
n is 1 or2;
m is 0 or 1;
R1 and R2 are each independently halogen, —
CN, —
R, —
OR, —
C1-6 perfluoroalkyl, or —
OC1- 6 perfluoroalkyl;
each R is independently hydrogen or a C1-6 alkyl group;
R3 and R4 are taken together, with the carbon atoms to which they are bound, to form a saturated or unsaturated 4-8 membered ring, wherein said ring is optionally substituted with 1-3 groups independently selected from halogen, —
R, or OR; and
R5 and R6 are each independently —
R; and
(c) optionally a pharmaceutically acceptable carrier, adjuvant, or vehicle.
2 Assignments
0 Petitions
Accused Products
Abstract
Therapeutic combinations useful in the treatment or prevention of psychotic disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of psychotic disorders are provided. Such compounds are of formula I:
or a pharmaceutically acceptable salt thereof, wherein each of R1, R2, R3, R4, R5, R6, n, and m are as defined and described herein.
-
Citations
20 Claims
-
1. A composition comprising:
-
(a) either a typical or atypical anti-psychotic drug;
(b) a compound of formula I;
or a pharmaceutically acceptable salt thereof, wherein;
designates a single or double bond;
n is 1 or2;
m is 0 or 1;
R1 and R2 are each independently halogen, —
CN, —
R, —
OR, —
C1-6 perfluoroalkyl, or —
OC1- 6 perfluoroalkyl;
each R is independently hydrogen or a C1-6 alkyl group;
R3 and R4 are taken together, with the carbon atoms to which they are bound, to form a saturated or unsaturated 4-8 membered ring, wherein said ring is optionally substituted with 1-3 groups independently selected from halogen, —
R, or OR; and
R5 and R6 are each independently —
R; and
(c) optionally a pharmaceutically acceptable carrier, adjuvant, or vehicle. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
Specification